EUVIMEDEUVIMED entdecken
Crossref

Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementation

Chuong Dinh Nguyen, Luan Minh Dang

World Journal of Gastroenterology · 28.07.2026 · 32 (28)

DOI: 10.3748/wjg.119462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 28.07.2026. Verfasst von Chuong Dinh Nguyen und 1 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The growing burden of inflammatory bowel disease (IBD) has increased pressure on healthcare systems to deliver effective biologic therapy at sustainable cost. Biosimilars offer an important opportunity to expand access to advanced treatment, yet their uptake in IBD remains inconsistent despite substantial evidence supporting comparable efficacy, safety, and immunogenicity. In this opinion review, we examine the current evidence for biosimilar use in IBD, including biologic-naive initiation, single switching, multiple switching, and emerging reverse-switch data. We also analyze the key controversies that continue to impede adoption, particularly immunogenicity, indication extrapolation, non-medical switching, and switch-back decisions. Beyond evidence-level debates, we examine the multi-level barriers that shape biosimilar implementation in practice, including the nocebo effect, physician hesitation, and system-level implementation constraints. We further propose a pragmatic 5-step framework to support structured biosimilar initiation or switching in routine IBD care. Finally, we consider the distinctive challenges of biosimilar implementation in resource-limited settings and introduce the concept of a “nocebo-prone environment” as a proposed explanatory lens for understanding barriers to equitable biosimilar integration.

Zitieren

APA

Nguyen, C. D., & Dang, L. M. (2026). Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementation. World Journal of Gastroenterology, 32(28). https://doi.org/10.3748/wjg.119462

Vancouver

Nguyen CD, Dang LM. Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementation. World Journal of Gastroenterology. 2026;32(28). doi:10.3748/wjg.119462

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Chuong Dinh and Dang, Luan Minh},
  title = {Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementation},
  journal = {World Journal of Gastroenterology},
  year = {2026},
  volume = {32},
  number = {28},
  doi = {10.3748/wjg.119462}
}
Kostenlos starten →